On June 1, 2026, Resmed, a medical device company that develops, manufactures, and distributes medical equipment for the diagnosis, treatment, and management of respiratory disorders, announced it has closed on its acquisition of Noctrix Health, a medical device company that developed and manufactures a novel therapy to treat drug-refractory Restless Legs Syndrome (RLS) for $340 million. Wilson Sonsini Goodrich & Rosati advised Noctrix on the transaction.

As part of the acquisition, Resmed will invest in R&D, sales, and marketing, helping Noctrix expand its market access.

The Wilson Sonsini corporate team that advised Noctrix on the transaction includes Elton Satusky, Brian Appel, Daniel Cho, Victor MacDiarmid, Riven Bu, and Zachary Shen.

For more information, please see Resmed and Noctrix’s joint press release.